The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
HTG Announces New Australian Patent for Its Technology
Feb. 26, 2018 04:23PM PST
Medical Device InvestingHTG Molecular Diagnostics (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the issuance of Australian Patent Number 2012316129 for “Methods of Co-detecting mRNA and Small Non-coding RNA.” As quoted in the press release: “We are pleased to strengthen our intellectual property protection with the addition of this Australian patent …
HTG Molecular Diagnostics (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the issuance of Australian Patent Number 2012316129 for “Methods of Co-detecting mRNA and Small Non-coding RNA.”
As quoted in the press release:
“We are pleased to strengthen our intellectual property protection with the addition of this Australian patent covering this application of our core technology,” stated TJ Johnson, Chief Executive Officer of HTG. “We believe miRNAs are gaining relevance as possible diagnostic markers and are very pleased to have our methods of mRNA and miRNA co-detection patented in multiple geographies. We have consistently sought to protect uses of our technology in the U.S. and globally, and now have over 20 patents covering our nuclease-protection-based technologies, including our HTG EdgeSeq method.”
Outlook Reports
Featured Medical Device Investing Stocks
Browse Companies
MARKETS
COMMODITIES
| Commodities | |||
|---|---|---|---|
| Gold | 2330.95 | +14.64 | |
| Silver | 27.37 | +0.19 | |
| Copper | 4.56 | +0.02 | |
| Oil | 83.75 | +0.18 | |
| Heating Oil | 2.56 | 0.00 | |
| Natural Gas | 1.56 | -0.08 | |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.